There are currently 70 active clinical trials seeking participants for Atrial Fibrillation research studies. The states with the highest number of trials for Atrial Fibrillation participants are Florida, California, Ontario and Texas.
High-resolution MRI of Atrial Fibrillation Patients Prior to Focal Impulse and Rotor Modulation (FIRM) Ablation
NCT03444337
Recruiting
Patients undergoing FIRM guided ablation of atrial fibrillation will undergo high resolution MRI imaging to determine correlation of underlying anatomic fibrotic regions with FIRM targeted sites for ablation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: Ohio State University, Columbus, Ohio
Conditions: Atrial Fibrillation
Register for Updates
Biomarkers of Acute Stroke in Clinic
NCT03897478
Recruiting
The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic strokes, when hemorrhagic stroke is ruled out, as defined by TOAST classification of subtypes of acute ischemic stroke. Aim 2: In cases of ischemic strokes of unknown or "cryptogenic" etiology, determine the ability of biomarker blood tests to predict etiology between... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/26/2023
Locations: Ohio Health Riveside Methodist Hospital, Columbus, Ohio
Conditions: Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Register for Updates
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
NCT06802081
Recruiting
This is a single center randomized double blind controlled study of patients (BMI\> 30 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/02/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Atrial Fibrillation, Obesity
Register for Updates
Intracardiac Echocardiography Guided Watchman Device Implant
NCT06007872
Recruiting
This study is to look at the success of Intracardiac Echocardiography (ICE) in the Watchman procedure. Currently the process is to use a Transesophageal Echocardiography (TEE) to place the Watchman in patients. This study is aiming to show how the ICE is just as effective in placing the device correctly and effectively.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Atrial Fibrillation, Left Atrial Appendage Thrombosis
Register for Updates
Development of CIRC Technologies
NCT05654272
Recruiting
Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which mark... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Cardiovascular Innovation Research Center, Cleveland, Ohio
Conditions: Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Metabolic Cardiomyopathy, Congenital Heart Disease, Aortic Diseases, Atrial Fibrillation, Ventricular Fibrillation
Register for Updates
Ondansetron for the Management of Atrial Fibrillation
NCT05844501
Recruiting
"Afib" is a common irregular heartbeat. Afib can cause stroke, blood clots, dementia and death. Medicines used to treat Afib often do not work well and can cause serious side effects. Clinicians need medicines that work better for Afib. Medicines for Afib work by blocking a current in the heart called a potassium current. There is a newer potassium current called IKas that can contribute to Afib. A medicine called ondansetron is used to keep people with cancer from getting sick to their stomach... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/27/2025
Locations: Indiana Clinical Research Center, Indianapolis, Indiana +2 locations
Conditions: Atrial Fibrillation
Register for Updates
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NCT06455098
Recruiting
The purpose of this study is to demonstrate the safety and 12-month effectiveness of the BWI OMNYPULSE™ pulsed field ablation (PFA) platform for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF), an irregular heart rate that causes abnormal blood flow.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/22/2025
Locations: Phoenix Cardiovascular Research Group, Phoenix, Arizona +45 locations
Conditions: Atrial Fibrillation
Register for Updates
The CONFORM Pivotal Trial
NCT05147792
Recruiting
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Grandview Medical Center, Birmingham, Alabama +59 locations
Conditions: Atrial Fibrillation, Stroke
Register for Updates
SIMPLAAFY Clinical Trial
NCT06521463
Recruiting
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Grandview Medical Center, Birmingham, Alabama +65 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698
Recruiting
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Affinity Hospital dba Grandview Medical Center, Birmingham, Alabama +52 locations
Conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Register for Updates
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
NCT05357690
Recruiting
The purpose of this study is to test if a nerve block procedure called a stellate ganglion block can help decrease the chance of atrial fibrillation after surgery. Atrial fibrillation is the abnormal, fast beating of the upper chambers of the heart. Stellate ganglion blockade has shown to decrease other types of abnormal heart rhythms as well as decrease the chance of atrial fibrillation.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/10/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Atrial Fibrillation
Register for Updates
Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation
NCT05190679
Recruiting
This is a prospective, case-control study that seeks to learn about the role of genetics in early onset atrial fibrillation (AF) and if genetic testing can be used to improve how the investigators treat atrial fibrillation. The study will enroll 225 participants. Eligible participants will have undergone sequencing for arrhythmia and cardiomyopathy (CM) genes. Based on those results, participants will be recruited for an outpatient research visit with testing that includes cardiac MRI, rest/stre... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
05/08/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Atrial Fibrillation
Register for Updates